Unitaid Official Discusses HIV Treatment Pricing Deal In Intellectual Property Watch Interview

Intellectual Property Watch: Unitaid Official Explains How ‘Breakthrough’ HIV Medicine Pricing Deal Brings Best To The Neediest
“…In the midst of the high-level meetings of the annual United Nations General Assembly last week, health officials from the U.N. and foundations announced what they called a breakthrough pricing agreement that will speed the availability of ‘the first affordable, generic, single-pill HIV treatment regimen containing (the key compound) dolutegravir to public sector purchasers in low- and middle-income countries at around $75 per person, per year.’ … In an interview with Intellectual Property Watch after the press conference, Unitaid’s Philippe Duneton explained in detail how the agreement came into being and why it is so important…” (New, 9/25).

The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.

KFF Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270

www.kff.org | Email Alerts: kff.org/email | facebook.com/KFF | twitter.com/kff

The independent source for health policy research, polling, and news, KFF is a nonprofit organization based in San Francisco, California.